more_reports

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

  ()
PolyPid enters a major commercialization deal with Azurity for D-PLEX100 targeting surgical site infections, with upfront payments and milestone potential supporting retail investors watching PYPD progress toward 2027 launch.
Tags: Biotechnology / Pharmaceuticals

PolyPid, Azurity Sign US$330M Deal for D-PLEX100

  ()
PolyPid Ltd. (PYPD:NASDAQ) and Azurity Pharmaceuticals signed a deal worth up to US$330 million to commercialize D-PLEX100, an infection-prevention drug, in the U.S. and Canada.
Tags: Biotechnology / Pharmaceuticals

BioMarin Advances VOXZOGO Toward Full FDA Approval

  ()
BioMarin submits sNDA for traditional VOXZOGO approval in achondroplasia with a Feb 2027 PDUFA date backed by extensive long-term data and an expanding skeletal dysplasia market opportunity.
Tags: Biotechnology / Pharmaceuticals

Biotech Advances VOXZOGO Toward Landmark US FDA Approval

  ()
BioMarin Pharmaceuticals Inc.'s (BMRN:NASDAQ) supplemental New Drug Application seeking traditional approval for VOXZOGO (vosoritide) to treat children with the genetic bone-growth disorder achondroplasia has been accepted.
Tags: Biotechnology / Pharmaceuticals

Digital Health Platform Achieves SOC 2 Milestone in Booming Sector

  ()
Rocket Doctor AI reaches SOC 2 Type I compliance, strengthening its enterprise position as the digital health market expands rapidly with rising AI adoption.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Healthcare Platform Clears Major Security Milestone After Independent Audit

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) said its wholly owned Rocket Doctor platform achieved SOC 2 Type I compliance following an independent third-party audit of its security, privacy, and operational controls.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale

  ()
Summit Therapeutics Inc. (SMMT:NASDAQ; SUMM:LON) is selling its Phase 3 antibiotic to Biossil for up to US$104.5 million in milestones, refocusing on its oncology drug ivonescimab.
Tags: Biotechnology / Pharmaceuticals

Houston ALS Biotech Coya Eyes 2028 Approval Path

  ()
Coya Therapeutics advances COYA 302 for ALS with strong analyst support and a key 2027 readout ahead. Discover the catalysts and industry trends driving this Houston biotech.
Tags: Biotechnology / Pharmaceuticals

Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target

  ()
Roth, Chardan Capital, and H.C. Wainwright have all issued "Buy" ratings on Coya Therapeutics Inc. (COYA:NASDAQ) in 2026. Read on to find out why analysts are intrigued.
Tags: Biotechnology / Pharmaceuticals

DarioHealth AI Platform Targets 10-15% Revenue Growth from Existing Clients

  ()
DarioHealth's DarioIQ AI engine is positioned to lift B2B2C recurring revenue 10-15% from current customers while the AI healthcare market expands rapidly toward hundreds of billions.
Tags: TechnologyHealthcare ServicesLife Sciences Tools & DiagnosticsArtificial Intelligence

AI Engine Delivers Engagement Gains as Recurring Revenue Outlook Climbs

  ()
DarioHealth Corp. (DRIO:NASDAQ) said its DarioIQ platform reflects the ongoing digital health rotation and AI transformation across healthcare, with broader deployment expected to increase recurring revenue from existing customers by 10% to 15%.
Tags: Life Sciences Tools & DiagnosticsHealthcare ServicesTechnologyArtificial Intelligence

Pet Odor Market Ignites BioLargo Consumer Comeback

  ()
BioLargo re-enters the booming U.S. pet odor control market with a direct-to-consumer CupriDyne brand, building on proven demand while advancing water treatment and medical technologies for retail investors.
Tags: TechnologySpecial SituationsHealthcare ServicesLife Sciences Tools & DiagnosticsCleantech

Cleantech Co. Relaunches Pet Brand Under Its Own Control

  ()
BioLargo Inc. (BLGO:OTCQX) unveils plans to reintroduce its enormously popular CupriDyne-based pet odor products to the consumer market. This time, the company says it will own the brand and do it its own way.
Tags: TechnologySpecial SituationsHealthcare ServicesLife Sciences Tools & DiagnosticsCleantech

Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.
Tags: Biotechnology / Pharmaceuticals

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win

  ()
Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity.
Tags: Biotechnology / Pharmaceuticals

Biotech With Muscle Disease Drug Uncovers Results in Trial Data

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Digital Health Platform Lands Access to Hundreds of Thousands of Covered Lives

  ()
DarioHealth Corp. (DRIO:NASDAQ) signed a new agreement through its Amwell partnership that makes its cardiometabolic platform available to a major Arizona health insurer's ASO business, representing hundreds of thousands of covered lives.
Tags: Healthcare Services

NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss

Research Report
  ()
The FDA accepted the company's morpholino oligomer filings with a February 2027 PDUFA date, but a missed confirmatory trial endpoint clouds its path to full approval.
Tags: Biotechnology / Pharmaceuticals

Grey Matters Health Inc. Targets Alzheimer's PET Imaging Opportunity

  ()
Grey Matters Health Inc. advances first U.S. brain-dedicated PET clinic for Alzheimer's detection amid surging diagnostics demand. Learn the key facts for investors.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew

  ()
BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.
Tags: Life Sciences Tools & DiagnosticsTechnologyBiotechnology / PharmaceuticalsSpecial Situations

First-of-Its-Kind US Brain Imaging Clinic Takes Delivery of Key PET Scanner

  ()
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) received its first brain-dedicated PET scanning system for its flagship Florida NovaScan Neuroimaging Clinic, which the company said will be the first U.S. facility dedicated to brain-only PET imaging for Alzheimer's disease and other neurological conditions.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services